2019 · Human pilot
Senolytics in people: the first tissue-level signals
A small clinical study moved the senescent-cell hypothesis beyond animal models.
Research publication: 2019-09-18 · English briefing: 18 September 2026
What the research found
Hickson and colleagues studied nine people with diabetic kidney disease in an open-label pilot of dasatinib plus quercetin. Tissue and blood analyses after treatment showed reductions in several senescence-associated measures. This provided an early human signal that a senolytic approach could affect its intended biological target. It did not demonstrate that the participants lived longer or that the same approach benefits healthy people.
Where the evidence stops
The study was small and short, with no randomised control group. Changes in cellular markers cannot establish long-term safety or improvements in disability, disease events or survival. Prescription-drug risks remain relevant.
The private-client perspective
A useful research briefing distinguishes target engagement from a meaningful health outcome. For clients considering a new intervention, both are important, but they answer different questions. The practical priority is to understand the intended indication, the strength of the evidence and the alternatives. A premium service should make that evidence easier to assess rather than make an experimental drug appear routine.
Read the source
An independent editorial synthesis of published research, not an original NoahThera study or a personal medical recommendation. Evidence stages are identified above; cited researchers and institutions are not represented as NoahThera partners.